Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | QPCT | Q16769 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | TEK | Q02763 | 2/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.32 |
| ▸ | ACP1 | P24666 | 1/20 | 0.32 |
| ▸ | ERCC1 | P07992 | 2/20 | 0.32 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3038470 | 0.86 | EPHB4 (0.35) | POLBKDRTEKEPHB4L3MBTL1 | |
| SCHEMBL3051555 | 0.84 | QPCT (0.38) | POLBQPCT | |
| SCHEMBL3051311 | 0.84 | QPCT (0.37) | POLBQPCTWDR5KMT2A | |
| SCHEMBL3047194 | 0.82 | HTT (0.35) | POLBQPCTTEKEPHB4KMT2A | |
| SCHEMBL3037465 | 0.82 | POLB (0.33) | POLBQPCTTEKEPHB4L3MBTL1 | |
| SCHEMBL3034900 | 0.81 | TEK (0.43) | LMNAKDRTEKEPHB4 | |
| SCHEMBL3041969 | 0.79 | QPCT (0.37) | QPCT | |
| Trifluoroacetic Acid SCHEMBL3049022 | 0.78 | TAAR1 (0.52) | LMNAPOLBQPCTL3MBTL1KMT2A | |
| SCHEMBL3044920 | 0.77 | MTOR (0.36) | — | |
| SCHEMBL3823826 | 0.72 | MAOB (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | LMNA 4551/4885POLB 4000/4885QPCT 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.